LOGIN  |  REGISTER
C4 Therapeutics

AMN Healthcare Introduces Televate™ Teletherapy Platform for Students K-12

July 30, 2024 | Last Trade: US$39.67 0.26 0.66

DALLAS, July 30, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare, the nation’s leading healthcare workforce solutions company, is introducing a new teletherapy platform designed to increase access to therapy services for students nationwide. “Televate™,” as the platform is called, allows school therapists, including psychologists, speech language pathologists and others, to conduct sessions in virtual therapy rooms, manage their scheduling, attendance, referrals and document uploads all in one secure location.

“The need for school-based therapy services is increasing, while access to therapists is limited,” said Kristin Martinez, M.A., CCC-SLP, Senior Director, Teletherapy with AMN Healthcare. “Televate offers an innovative way to expand access to individualized, essential services in underserved areas and other school districts where these services are urgently needed.”

While teletherapy now is available to some students, Televate offers unique features that create a new level of care, according to Martinez. Some current student teletherapy sessions take place on platforms designed for conference calls and webinars that were not developed to support high-quality therapy and evaluation services for children. Televate, by contrast, provides features designed to increase ease of student access, while engaging and empowering students to reach their developmental and academic goals, Martinez said.

These features include capacity for individual and group sessions, second camera integration, adjustable video feeds, and collaborative tools, including a whiteboard and greenscreen. In addition, clinicians can access a therapy room with integrated materials and assessments from leading publishers to meet standardized virtual evaluation requirements.

“Televate is a high-tech resource intended to achieve a high-touch outcome,” said Patrick O’Connor, President, School Solutions with AMN Healthcare. “It provides clinicians with everything they need to perform their jobs at an extremely high level, while allowing school districts to meet mandated therapy service requirements.”

Televate will be offered at the beginning of the 2024-2025 school year. Training on the platform will be provided to both school districts and clinicians staffed by AMN Healthcare. Throughout the school year, AMN Healthcare will partner with school districts and clinicians to make further enhancements to the platform if needed to better serve student needs.

For additional information about AMN Healthcare and its school staffing and technology services, visit https://www.amnhealthcare.com.

About AMN Healthcare  

AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.

Media Contact  
Corporate Communications  
AMN Healthcare  
This email address is being protected from spambots. You need JavaScript enabled to view it.  
Investor Contact  
Randle Reece  
Senior Director, Investor Relations & Strategy  
AMN Healthcare  
(866) 861-3229 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB